Tsumura & Co
TSE:4540

Watchlist Manager
Tsumura & Co Logo
Tsumura & Co
TSE:4540
Watchlist
Price: 3 376 JPY 0.09%
Market Cap: 259.1B JPY

EV/EBITDA
Enterprise Value to EBITDA

4.9
Current
6.6
Median
12.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
4.9
=
Enterprise Value
252.8B JPY
/
EBITDA
51.3B JPY
Market Cap EV/EBITDA
JP
Tsumura & Co
TSE:4540
255.7B JPY 4.9
US
Eli Lilly and Co
NYSE:LLY
776.5B USD 37.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
377.9B USD 12.7
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK 14.8
CH
Roche Holding AG
SIX:ROG
211.3B CHF 9.6
CH
Novartis AG
SIX:NOVN
189.7B CHF 10.7
UK
AstraZeneca PLC
LSE:AZN
170.1B GBP 131.3
US
Merck & Co Inc
NYSE:MRK
203.6B USD 8.7
IE
Endo International PLC
LSE:0Y5F
163.5B USD 261.3
US
Pfizer Inc
NYSE:PFE
139.5B USD 7.6
EBITDA Growth EV/EBITDA to Growth
JP
Tsumura & Co
TSE:4540
Average EV/EBITDA: 395
4.9
9%
0.5
US
Eli Lilly and Co
NYSE:LLY
37.5
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.7
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
14.8
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.6
5%
1.9
CH
Novartis AG
SIX:NOVN
10.7
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.3
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
4.9
2-Years Forward
EV/EBITDA
4.5
3-Years Forward
EV/EBITDA
3.8